(IN BRIEF) FinVector, a leading biopharmaceutical company, has inaugurated a cutting-edge production facility in Kuopio, Finland, aimed at manufacturing gene therapy products. The new Finport facility, which is set to become one of the world’s largest for such therapies, represents … Read the full press release
Posted in Banks, Business, Environment, Financial, Finland, Government, Healthcare, Industrial, Infrastructure & Utilities, Investment, Management, News, Pharma & Biotech, Science, Technology
Tagged cancer treatment, FinVector, Gene Therapy Facility, Jean-Frédéric Paulsen, KUOPIO, NIB, partnership, Petri Peltonen, Professor Seppo Ylä-Herttuala, Soile Lahti, sustainability
(IN BRIEF) Tubulis has been named one of 2024’s “Fierce 15” biotechnology companies by Fierce Biotech. This recognition celebrates Tubulis’ innovative work in ADC development and its commitment to improving cancer treatment outcomes. With significant recent advancements, including a €128 … Read the full press release
(IN BRIEF) Breakpoint Therapeutics GmbH, a company focused on developing drugs targeting the DNA Damage Response (DDR), has nominated its first preclinical development candidate, BTX-011, an inhibitor of polymerase theta (Pol θ / POLQ), for the treatment of solid tumors. … Read the full press release
(IN BRIEF) Tubulis has closed an oversubscribed €128 million ($138.8 million) Series B2 financing round, co-led by EQT Life Sciences and Nextech Invest Ltd, with participation from new and existing investors including Frazier Life Sciences and Deep Track Capital. The … Read the full press release
Posted in Business, Environment, Financial, Germany, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology
Tagged ADC Pipeline, cancer treatment, Christoph Broja, Deep Track Capital, Dominik Schumacher, EQT Life Sciences, Frazier Life Sciences, John de Koning, Kanishka Pothula, Nextech Invest Ltd, partnership, sustainability, TUB-030, TUB-040, Tubulis
(IN BRIEF) Fresenius Kabi announces FDA approval of Tyenne® (tocilizumab-aazg), the first tocilizumab biosimilar offering both IV and subcutaneous formulations. This marks a significant milestone in the company’s growth strategy (#FutureFresenius) and expands treatment options for inflammatory, autoimmune diseases, and … Read the full press release
Posted in Business, Germany, Healthcare, Pharma & Biotech
Tagged #FutureFresenius, Actemra®, autoimmune diseases, Biosimilar, Cancer, cancer treatment, FDA, Food and Drug Administration, Fresenius Kabi, Genentech, Idacio®, inflammatory, inflammatory diseases, IV, IV formulation, Stimufend®, Subcutaneous formulation, subcutaneous tocilizumab biosimilar, tocilizumab, tocilizumab biosimilar, tocilizumab-aazg, Tyenne®
(IN BRIEF) In early 2024, Europe’s medical and research communities announced major breakthroughs in cancer care, highlighting new treatments like AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan for lung and breast cancer, and AstraZeneca’s Tagrisso for EGFR-mutated lung cancer. Diagnostic advancements … Read the full press release
Posted in Finland, Germany, Healthcare, Insurance, News, Pharma & Biotech, Science, Society, Switzerland, Technology, United Kingdom
Tagged accessible cancer solutions, AstraZeneca, Aviva, BioNTech, breast cancer, breast cancer screening, cancer care, cancer diagnostics, cancer prevention awareness, cancer research, cancer treatment, colorectal cancer, Daiichi Sankyo, datopotamab deruxtecan, Duality Biologics, Eckert & Ziegler, EMA, FDA, genetic risk information, Inspirna, lung cancer, Merck KGaA, multi-cancer early detection, neuroendocrine neoplasms diagnostics, Novartis, ompenaclid, oncology, polygenic risk score, preventive healthcare, Professor Tim Maughan, ReSisTrace methodology, Stage III EGFR-mutated lung cancer, Swiss Re Institute, Tagrisso, treatment-resistant cancer cells, University of Helsinki, University of Liverpool
(IN BRIEF) Merck, a leading science and technology company, is set to present 28 abstracts at the 2023 European Society of Medical Oncology (ESMO) Annual Meeting in Madrid. These abstracts will showcase the latest research on Merck’s oncology portfolio, addressing … Read the full press release
Posted in Business, Germany, Healthcare, Management, Media, News, Pharma & Biotech, Science, Spain, Technology
Tagged BAVENCIO™, bladder, cancer treatment, colorectal, ERBITUX, ESMO 2023, head and neck, lung, Madrid, Merck, oncology, TEPMETKO, Xevinapant
(PRESS RELEASE) CAMBRIDGE, 16-Jan-2023 — /EuropaWire/ — AstraZeneca (LSE/STO/Nasdaq: AZN), a British-Swedish multinational pharmaceutical and biotechnology company, has announced the completion of its acquisition of Neogene Therapeutics Inc. Neogene is a global clinical-stage biotechnology company that specializes in the discovery, … Read the full press release
EQT Infrastructure has agreed to acquire Icon Group from a consortium including Goldman Sachs Asset Management, QIC and Pagoda. Goldman Sachs Asset Management will remain a minority shareholder as part of the transaction Icon Group is Australia’s largest vertically integrated cancer … Read the full press release
Posted in Business, Healthcare, Investment, Management, News, Pharma & Biotech, Science, Sweden, Technology
Tagged acquisition, Australia, Blikk, cancer care, cancer clinical trials, cancer drug infusions, cancer patients, cancer treatment, compounding, decentralisation, Deloitte, diagnostic imaging provider, digitalization, EQT, EQT Infrastructure, EQT Infrastructure V, Goldman Sachs Asset Management, healthcare sector, Herbert Smith Freehills, I-MED, Icon Group, integrated cancer-care operator, Integrated Clinical Oncology Network, investment, Jim Kelly, Ken Wong, Mark Middleton, medical oncology, Meine Radiologie Holding, Morgan Stanley, nuclear medicine, oncology, Pagoda Investment Advisors, pharmacy, PwC, QIC Private Capital Pty Ltd, Radiation Oncology, radiology, radiotherapy, Stephanie Hui
With millimetre precision, certain tumours can be irradiated at the Paul Scherrer Institute PSI using protons – that is, positively charged elementary particles. PSI is the one place in Switzerland where this especially protective and precise option for radiation therapy … Read the full press release
Option to add new biomarkers for microsatellite instability (MSI) and mismatch repair (MMR) to QIAGEN’ s NGS panels Hilden, Germany, and Germantown, Maryland, 07-Jun-2017 — /EuropaWire/ — QIAGEN (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced it has received a worldwide … Read the full press release
NEW YORK and HILDEN, Germany, 06-Jun-2017 — /EuropaWire/ — Bristol-Myers Squibb Company (NYSE: BMY) and QIAGEN(NASDAQ: QGEN; Frankfurt Prime Standard: QIA) have signed an agreement to explore the use of next-generation sequencing (NGS) technology to develop gene expression profiles (GEPs) as … Read the full press release
In collaboration with international scientists, researchers from the University of Copenhagen have developed a method to help shorten the road to better cancer treatment COPENHAGEN, 12-5-2015 — /EuropaWire/ — Danish researchers at the University of Copenhagen have discovered how to … Read the full press release
Posted in Denmark, Healthcare, Science, Technology
Tagged cancer treatment, mass spectrometry, Niels Mailand, University of Copenhagen
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?
PHARMA & BIOTECH: The largest repository of EU/European pharma & biotech press releases spanning 12 years (2012-2024)
